[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-877-240-9479

Email address

information.center@astrazeneca.com

Condition

Gastric Cancer

Treatment type

Interventional

Investigational product

AZD2936

Phase

Phase 2

Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT05702229

Study number

D7986C00001

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. 18 years or older at the time of signing the ICF.
  2. Body weight > 35 kg.
  3. Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
  4. Has measurable target disease assessed by the Investigator based on RECIST 1.1.
  5. ECOG PS 0 or 1.
  6. Life expectancy of at least 12 weeks.
  7. Adequate organ and bone marrow function.
Exclusion criteria

  1. Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by ISH] or indeterminate gastric or GEJ carcinoma.
  2. Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
  3. Participants with ascites which cannot be controlled with appropriate interventions.
  4. Active infectious diseases, including tuberculosis, HIV infection, or hepatitis A/B/C.
  5. Uncontrolled intercurrent illness.
  6. Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
  7. History of another primary malignancy.
  8. Previous treatment with an immune-oncology agent.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site